

بسم الله الرحمن الرحيم



-Caron-





شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم





جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها على هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغيار







Effects of tobacco use on psychotic symptoms in male nicotine-dependent subjects with psychotic disorders

A thesis

For fulfillment of Master Degree in Psychiatry

Submitted by

OLWY HAMED ABO ELNOUR

M.B.B.CH, Faculty of Medicine, Tanta University

Supervised by

Prof. Dr. Yasser Abdel Razek Mohammed

Professor of Psychiatry
Faculty of Medicine – Ain Shams University

Assist. Prof. Dalia Abdel Moneim Mahmoud

Assistant Professor of Psychiatry Faculty of Medicine – Ain Shams University

Dr. Mahmoud Hassan Ali Morsy

Lecturer of Psychiatry
Faculty of Medicine – Ain Shams University

Ain Shams University Faculty of Medicine 2021



سورة البقرة الآية: ٣٢



My thanks first to "Allah" who give me the ability and strength to complete this work

I would like to express my indebtedness and deepest gratitude to **Prof. Dr. Yasser Abdel Razek Mohammed**, Professor of Psychiatry, Faculty of Medicine, Ain Shams University for his valuable advice, guidance and constructive criticism, also for the invaluable assistance and efforts he devoted in the supervision of this study.

I'll never forget, how co-operative was **Dr. Dalia Abdel Moneim Mahmoud**, Assistant Professor of Psychiatry, Faculty of
Medicine, Ain Shams University, also she was encouraging all
the time. It is honorable to be supervised by her.

I would like also, to express my great thanks to **Dr**. **Mahmoud Hassan Ali Morsy**, Lecturer of Psychiatry, and Faculty of Medicine – Ain Shams University. His valuable advises and continuous support facilitated completing this work.

I'd like to give my wormiest appreciation to my family and my friends who always give me a great support.

I would like to thank my colleagues and everyone who made this work possible and enjoyable.

Olwy Hamed Abo Elnour 2021





List of Contents

| Subjects | Page |
|---|------|
| List of Abbreviations | |
| List of Tables | II |
| List of Figures | III |
| Introduction | 1 |
| Aim of the study | 4 |
| Review of Literature: | 5 |
| ♣ Chapter (1): An Overview on Nicotine Dependence | |
| Chapter (2): The Relationship between Nicotine Dependence and Psychotic Disorder | 11 |
| Chapter (3): Management of Nicotine Dependence in patients with Psychosis | 48 |
| Patients and Methods | 64 |
| Results | 71 |
| Discussion | 94 |
| Summary | 105 |
| Conclusion | 111 |
| Recommendation | 112 |
| References | 113 |
| Arabic Summary | 1 |

List of abbreviations

| CB1 | |
|----------|---|
| CDS | Cigarette Dependence Scale |
| CI | confidence interval |
| CMS | Centers for Medicare & Medicaid Services |
| CNS | Central nervous system |
| COX-2 | cyclooxygenase-2 |
| dACC | dorsal anterior cingulate cortex |
| DSM | Diagnostic and Statistical Manual of Mental Disorders |
| FGAs | First generation antipsychotics |
| fMRI | functional magnetic resonance imaging |
| FTCD | Fagerström Test for Cigarette Dependence |
| FTND | Fagerström Test of Nicotine Dependence |
| GABA | γ-aminobutyric acid |
| GWASs | genome-wide association studies |
| IQR | interquartile range |
| MR | Mendelian randomization |
| nAChRs | Nicotinic acetylcholine receptors |
| NDSS | Nicotine Dependence Syndrome Scale |
| NF-kB | nuclear factor kappa B |
| NMDA | N-methylD-aspartate |
| NNN | N'-nitrosonornicotine |
| NRT | Nicotine replacement therapy |
| NSDUH | National Survey on Drug Use and Health |
| PANSS | Positive and Negative Syndrome Scale |
| PET | positron emission tomography |
| PFC | prefrontal cortex |
| PPI | prepulse inhibition |
| SAES | Symptom Rating Scale |
| SCID I | Structured clinical interview for DSM-IV |
| SMH | self-medication hypothesis |
| SNP | nucleotide polymorphism |
| SPEM | smooth pursuit eye movements |
| SSD | schizophrenia spectrum disorders |
| TNP | transdermal nicotine patch |
| TSNAs | tobacco specific nitrosamines |
| VTA | ventral tegmental area |
| WISDM 68 | Wisconsin Inventory of Smoking Dependence Motives |

∠ist of tables

| List | Review | Page |
|--------------------|---|------|
| Table (1): | Studies showing nicotine as a carcinogen | 6 |
| Table (2): | Comparison of Smoking-related Parameters between Normal Smokers and Smokers with Schizophrenia | 28 |
| Table (3): | Odds Ratios Comparing Frequencies of Smoking- Related Prevalences among Patients with Schizophrenia versus General Population and Patients with Other Mental Illnesses | 31 |
| Table (4): | Strategies to Improve the Delivery of Treatment for Nicotine Dependence in Treatment in Health-Care Settings, Including Psychiatric Hospitals | 57 |
| List | Results | Page |
| Table (1): | Descriptive results of the demographic data of the whole sample | 74 |
| Table (2): | Descriptive results of the clinical data of the whole sample | 75 |
| Table (3): | Descriptive results of the smoking pattern in the studied cases | 76 |
| Table (4): | Comparison between the two studied groups according to demographic data | 78 |
| Table (5): | Comparison between the two studied groups according to clinical data | 81 |
| Table (6): | Distribution of the smoking pattern in the studied cases | 83 |
| Table (7): | Comparison between the two studied groups according to Panss-1 | 85 |
| Table (8a): | Comparison between the two studied groups according to structured clinical interview for DSM-IV score symptoms | 88 |
| Table (8b): | Comparison between the two studied groups according to structured clinical interview for DSM-IV score symptoms "continue" | 89 |
| Table (9): | Correlation between frequency of smoking with panss-1 and structured clinical interview for DSM-IV score in cases group | 91 |
| Table (10): | Correlation between duration of smoking with panss-1 and structured clinical interview for DSM-IV score in cases group | 92 |

| Correlation between FTCD with panss-1 and | |
|---|----|
| structured clinical interview for DSM-IV score in | 93 |
| cases group | |

List of figures

| List | Review | Page |
|------------|---|------|
| Figure (1) | Nicotinic receptor subtypes mainly implicated in schizophrenia. In schizophrenia, upregulation of $\alpha 4\beta 2$ leads to early initiation, and downregulation of $\alpha 7$ leads to increased persistence and severity of smoking behavior | 30 |
| Figure (2) | Overview of theoretical models of smoking in schizophrenia. Various theoretical models complement each other to explain the increased smoking in schizophrenia. | 34 |
| Figure (3) | Self-medication and affect dysregulation hypotheses in schizophrenia. Violet solid lines () denote SMH and green dashed lines () denote affect dysregulation hypothesis of higher tobacco dependence among patients with schizophrenia. DA, dopamine; Glu, glutamate | 36 |
| Figure (4) | Outline of pathophysiology of smoking in schizophrenia—an insight into the addiction vulnerability hypothesis. Common biological vulnerabilities associated with schizophrenia and their interactions with nicotine explain the high comorbidity. CHRNA7, genes encoding cholinergic receptor (nicotinic) α 7 (likewise A3, A4, A5, B2: similar receptors α 3, α 4, α 5, β 2); dACC: dorsal anterior cingulate cortex | 38 |
| Figure (5) | Past 30-day use (%) of specific tobacco products among adults with no past-year mental illness | 50 |
| Figure (6) | Past 30-day use (%) of specific tobacco products among adults reporting receipt of inpatient mental health treatment in the past year | 51 |
| Figure (7) | Global coverage of smoke-free policies in public places. The acknowledgment of the harms of secondhand tobacco smoke has led to the implementation of smoke-free policies in public places | 54 |
| Figure (8) | Global availability of smoking cessation support. Smoking cessation support is available in most countries globally | 56 |

| Figure (9) | Change in proportion (%) of the recording of five elements of treatment for tobacco dependence in audited medical records of an Australian inpatient psychiatric hospital | 59 |
|-------------|---|------|
| List | Results | Page |
| Figure (1) | Comparison between the two studied groups according to age | 79 |
| Figure (2) | Comparison between the two studied groups according to Education | 79 |
| Figure (3) | Comparison between the two studied groups according to Dose of antipsychotics | 82 |
| Figure (4) | Comparison between the two studied groups according to Type of antipsychotic | 82 |
| Figure (5) | Distribution of the studied cases according to Types of smoking | 84 |
| Figure (6) | Distribution of the studied cases according to Frequency of smoking | 84 |
| Figure (7) | Comparison between the two studied groups according to Panss-1 | 86 |
| Figure (8) | Comparison between the two studied groups according to structuredclinical interview for DSM-IV score total | 90 |
| Figure (9) | Correlation between frequency of smoking with panss-1 and structured clinical interview for DSM-IV score in cases group | 91 |
| Figure (10) | Correlation between Duration of smoking with panss- 1 and structured clinical interview for DSM-IV score in cases group | 92 |
| Figure (11) | Correlation between FTCD with panss-1 and structured clinical interview for DSM-IV score in cases group | 93 |

INTRODUCTION

A meta-analysis has demonstrated that smoking prevalence among young people at the time of presentation for treatment of first-episode psychosis is around 60%, and six times higher than in age- and gendermatched controls (**Arnott et al., 2013**).

One of the most severe psychotic disorders is schizophrenia. It has long been acknowledged that there is a strong relationship between cigarette smoking and psychotic disorders. More recently, smoking has also been found to be associated with psychotic experiences in the general population (Quigley and MacCabe, 2019).

Between 72% and 90% of schizophrenic patients smoke cigarettes compared with 24% of the general population. Patients with schizophrenia smoke many more cigarettes on average per day, and often spend one third of their weekly income on cigarettes. In addition, some studies have found that these patients have higher serum levels of cotinine, the primary metabolite of nicotine (**Evins, 2008**).

Approximately 60% to 80% of current smokers fulfill classic criteria for drug dependence; e.g., they have difficulty stopping, have withdrawal when they stop, are tolerant and continue despite knowledge of personal harm (AAAP, 2015).

There has been emerging evidence of an association between tobacco smoking and schizophrenia spectrum disorders (SSD). There was substantial though inconclusive evidence supporting a causal relationship between tobacco smoking and increased risk of SSD. If a causal relationship does exist, nicotine is most likely responsible for this association (Scott et al., 2018).

Data indicate that the smoking rate in schizophrenia is also somewhat higher compared to that seen in other psychiatric disorders, such as mood disorder and bipolar disorder. In the latter condition, prevalence and severity of smoking is found to be associated with the severity of psychotic symptoms (**Kumaria & Postma, 2005**).

The reason for the increased rate of cigarette smoking in patients with schizophrenia is uncertain. The "self-medication" theory suggests that schizophrenic patients smoke cigarettes to reduce the severity of their positive and negative symptoms and to improve their cognitive functions. It is thought that nicotine reduces negative symptoms and improves cognitive functions by causing a temporary increase in the activity of the mesocortical dopamine system. (Baran Tatar, 2018)

The rates of tobacco addiction in individuals with psychiatric disorders (mental illness and addiction) continue to remain alarmingly high despite substantial decreases in smoking in the general population (Ziedonis & Williams, 2003).

Rationale:

Although the association between psychotic illness and cigarette smoking is well known, the reasons are unclear why people with psychosis are more likely to smoke than are the general population. (Gurillo et al., 2015)

The relationship between tobacco use and Schizophrenia spectrum disorders (SSD) remained significant even after adjusting for factors that might confound the relationship including family socio-economic status, cannabis use, parental substance abuse and parental psychosis. (Scott et al., 2018)

People with schizophrenia are three times more likely to smoke than other people and they tend to smoke more heavily. One of the most common explanations of this is that people with schizophrenia use smoking to control ormanage some of the symptoms associated with their illness and to reduce some of the side effects of their medication (Mental Health Foundation, 2007)

Hypothesis:

The study presents a hypothesis that psychotic symptoms are probably severer in patients with nicotine dependence than patients who don't smoke, and that there may be a positive correlation between severity of nicotine dependence and severity of psychotic symptoms found in patients with psychosis who have nicotine dependence.